Fig. 2
From: A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
Serum biomarkers in peripheral spondyloarthritis. Effect of nilotinib and placebo on serum biomarkers of patients with peripheral spondyloarthritis. The panel represents the C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), calprotectin and matrix metalloproteinase-3 (MMP-3) levels before (week 0) and after treatment (week 12) with nilotinib (a–d) or placebo (e–h). The lines connect the data points for each patient. *P value <0.05